Ashu Tyagi, Director at Y-mAbs Therapeutics, Inc. (YMAB), bought 430,174 shares at $16.00 ($6.9M) on 2018-09-25, disclosed to the SEC on 2018-09-26.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.